Press release
Axial Spondyloarthritis (axSpA) Market 2024 Report By Key Companies, Regional Analysis And Forecast 2033
Axial Spondyloarthritis (axSpA) Market
The Business Research Company offers in-depth market insights through Axial Spondyloarthritis axSpA Global Market Report 2024, providing businesses with a competitive advantage by thoroughly analyzing the market structure, including estimates for numerous segments and sub-segments.
Market Size And Growth Forecast:
The axial spondyloarthritis (axspa) market size has grown strongly in recent years. It will grow from $5.54 billion in 2023 to $6.04 billion in 2024 at a compound annual growth rate (CAGR) of 9.0%. The growth in the historic period can be attributed to improved diagnostic criteria, biological treatment advancements, rising disease awareness, genetic research advances, clinical trial progress.
The axial spondyloarthritis (axspa) market size is expected to see strong growth in the next few years. It will grow to $8.18 billion in 2028 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to advancements in biomarker identification, tailored therapies, digital health integration, expanded treatment options, healthcare policy support:. Major trends in the forecast period include early intervention strategies, patient-centric care, telemedicine and remote consultations, research on disease mechanisms, shared decision-making.
Get Free Sample Of This Report-
https://www.thebusinessresearchcompany.com/sample.aspx?id=12590&type=smp
Market Segmentation:
The axial spondyloarthritis (axspa) market covered in this report is segmented -
1) By Types: Ankylosing spondylitis (AS), Non-radiographic axial spondyloarthritis (nr-axSpA)
2) By Commercialized Therapies: Anti-tumor Necrosis Factor Therapy (TNF), Anti-Interleukin Therapy (IL), Anti-Janus Kinase Therapy (JAK)
3) By Dosage Form: Tablets, Injections
4) By Treatment: Tumor necrosis factor (TNF) Alpha Inhibitors, Non-steroidal anti-inflammatory drugs (NSAID), Conventional Disease Modifying Anti-Rheumatic Drugs, Glucocorticoids, Interleukin Blockers
5) By End-Use: Hospital Pharmacies, Retailer Pharmacies, Online Pharmacy Stores
Major Driver - Rising Prevalence Of Axial Spondyloarthritis (AXSPA) Is A Catalyst For Market Growth And Advancements In Treatment
The increasing prevalence of spondyloarthritis is expected to propel the growth of the axial spondyloarthritis (axSpa) market going forward. Spondyloarthritis is a chronic illness that typically affects the axial skeleton, including the spine and sacroiliac joints. The rising cases of spondyloarthritis (axSpA) can be associated with the increasing aging population and spine injuries from even minor falls or other accidents, where various treatments are provided for pain management, inflammation control, and enhancing the patient's quality of life suffering from axSpA. For instance, in June 2023, according to Versus Arthritis's Musculoskeletal Health Report 2023, a UK-based charity dedicated to supporting people with arthritis, as of the year 2022, around 60,000 individuals were afflicted with axial spondyloarthritis, and annually, approximately 2,200 adults receive a new diagnosis for this condition. Therefore, the increasing prevalence of axial spondyloarthritis (axSpa) is driving the growth of the axial spondyloarthritis (axSpa) market.
Competitive Landscape:
Major companies operating in the axial spondyloarthritis (axspa) market report are Johnson and Johnson Private Limited, Pfizer Inc., F. Hoffmann-La Roche AG, Merck and Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A, Bristol-Myers Squibb Company, AstraZeneca plc., Abbott Laboratories, GSK plc., Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Biogen Inc., Vertex Pharmaceuticals Incorporated, UCB S.A., Boehringer Ingelheim International GmbH., Horizon Therapeutics Public Ltd Co, Mitsubishi Tanabe Pharma Corporation, Ipsen Technologies Pvt Ltd., Kyowa Kirin Co. Ltd., Sun Pharmaceutical Industries Ltd., Acelyrin Inc., Nordic Bioscience A/S, Iroko Pharmaceuticals LLC, Celgene Corporation, Pozen Inc.
Get Access To The Full Market Report -
https://www.thebusinessresearchcompany.com/report/axial-spondyloarthritis-axspa-global-market-report
Top Trend - UCB Sa Secures Eu Approval For Bimzelx In Treating Axial Spondyloarthritis (AXSPA)
Product innovations are the key trend gaining popularity in the axial spondyloarthritis (axSpA) market. Major companies operating in the axial spondyloarthritis (axSpA) market are developing new drugs to sustain their position in the market. For instance, in June 2023, UCB SA, a Belgium-based pharmaceutical company, received approval from the New European Commission for the marketing authorization of BIMZELX (bimekizumab). This medication is used to treat adults with active axial spondyloarthritis (axSpA), non-radiographic axial spondyloarthritis (nr-axSpA), and ankylosing spondylitis (AS) with objective signs of inflammation as indicated by elevated C-reactive protein. These European Union (EU) authorizations represent the drug's first global marketing licenses for axial spondyloarthritis.
The Table Of Content For The Market Report Include:
1. Executive Summary
2. Axial Spondyloarthritis axSpA Market Characteristics
3. Axial Spondyloarthritis axSpA Market Trends And Strategies
4. Axial Spondyloarthritis axSpA Market - Macro Economic Scenario
5. Axial Spondyloarthritis axSpA Market Size And Growth
…..
27. Axial Spondyloarthritis axSpA Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-mode
About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialize in various industries including manufacturing, healthcare, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Axial Spondyloarthritis (axSpA) Market 2024 Report By Key Companies, Regional Analysis And Forecast 2033 here
News-ID: 3434254 • Views: …
More Releases from The Business research company
Emerging Trends to Reshape the Surgical Energy Instruments Market: Innovative Te …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Surgical Energy Instruments Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
In the past few years, the market size of surgical energy instruments has seen substantial growth. The market which is projected to be worth $4.68 billion in 2024, is expected to inflate to $5.2…
2025-2034 Spatial omics Market Evolution: Disruptions, Innovations, and Untapped …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Spatial omics Market Through 2025?
In recent years, the size of the spatial omics market has seen rapid expansion. The estimations show an increase to $0.33 billion in 2025 from $0.3 billion in 2024, marking a compound annual growth rate (CAGR) of…
Global Sigmoidoscope Market Projected to Grow at 6.1% CAGR, Reaching $3.38 Billi …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Will the Sigmoidoscope Industry Market Size Be by 2025?
In recent years, there has been a significant increase in the size of the sigmoidoscope market. The market is projected to expand from $2.53 billion in 2024 to $2.67 billion in 2025, demonstrating a compound annual growth rate (CAGR)…
2025-2034 Refurbished MRI Systems Market Roadmap: Insights for Competitive Advan …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the Refurbished MRI Systems Market Size By 2025?
The market size for refurbished MRI systems has experienced robust growth in the past few years. It is expected to rise from $0.77 billion in 2024 to $0.85 billion in 2025, showcasing a compound annual growth rate (CAGR)…
More Releases for Spondyloarthritis
Axial Spondyloarthritis Market Dynamics Indicate Upward Trajectory Through 2034, …
DelveInsight's "Axial Spondyloarthritis Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Axial Spondyloarthritis, historical and forecasted epidemiology as well as the Axial Spondyloarthritis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Axial Spondyloarthritis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Axial Spondyloarthritis Market Forecast
https://www.delveinsight.com/sample-request/axial-spondyloarthritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
Axial Spondyloarthritis Pipeline Therapeutics Assessment Report 2024 (Updated)
DelveInsight's, "Axial Spondyloarthritis Pipeline Insight 2024" report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Axial Spondyloarthritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Axial Spondyloarthritis Research. Learn more about…
Axial Spondyloarthritis (axSpA) Industry - Key Market Dynamics and Trends
The axial spondyloarthritis (axspa) market size has grown strongly in recent years. It will grow from $5.54 billion in 2023 to $6.04 billion in 2024 at a compound annual growth rate (CAGR) of 9.0%. The growth in the historic period can be attributed to improved diagnostic criteria, biological treatment advancements, rising disease awareness, genetic research advances, clinical trial progress.
The axial spondyloarthritis (axspa) market size is expected to see…
Axial Spondyloarthritis Drug Market to see Rapid Growth by 2029
The global axial spondyloarthritis drug market is anticipated to grow at a considerable CAGR of 4.1% during the forecast period. The market is primarily driven by favourable conditions for pharmaceutical producers and the attention of various government agencies on enhancing the current healthcare infrastructure. These will lead to a rise in global demand for various drugs for treatment options for axial spondyloarthritis in the near future. Additionally, significant investment in research and…
Optimization Of Workflows To Catalyse The Axial Spondyloarthritis Treatment Mark …
Axial spondyloarthritis is a type of inflammatory arthritis which primarily affects the axial skeleton such as pelvic joints and spine. Generally ankylosing spondylitis (AS), an inflammatory disease of the sacroiliac joints and spine are collectively termed as axial spondyloarthritis.
The axial spondyloarthritis is divided in two stages namely non- radiographic and radiographic stage. Severe and chronic back pain is the major symptom of this complication along with buttock pain and pain…
Axial Spondyloarthritis Global Clinical Trials Review, H1, 2017
"The Report Axial Spondyloarthritis Global Clinical Trials Review, H1, 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"
About Axial Spondyloarthritis Market
Summary
GlobalData's clinical trial report, Axial Spondyloarthritis Global Clinical Trials Review, H1, 2017" provides an overview of Axial Spondyloarthritis clinical trials scenario. This report provides top line data relating to the clinical trials on Axial Spondyloarthritis. Report includes an overview of trial…
